Home/Arrivo BioVentures/Kelly Abernathy

KA

Kelly Abernathy

Chief Operating Officer

Arrivo BioVentures

Therapeutic Areas

Psychiatry Gastroenterology Critical Care

Arrivo BioVentures Pipeline

Drug	Indication	Phase
SP-624 (Forvisirvat)	Major Depressive Disorder	Phase 2
RABI-767	Predicted Severe Acute Pancreatitis	Phase 2

Leadership Team at Arrivo BioVentures

Stephen E. Butts

Chief Executive Officer

Head of Corporate Development

Chief Financial Officer

Chief Medical Officer

Senior Vice President, Scientific Affairs

Bruce Leuchter, MD

View full Arrivo BioVentures profile